Trial reportThe Journal of allergy and clinical immunology2017
Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective.
Trial report in The Journal of allergy and clinical immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00932828 (Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance), which is not on this map. Cited by 145 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study; Grant "Optimizing Tolerance Induction in Peanut Allergy: The DEVIL Study"
Who cites it
145 citing papers in PubMed, 3 syntheses or guidelines pooled it, 388 citations in OpenAlex.
- Guideline
- Racial and Ethnic Representation in Food Allergen Immunotherapy Trial Participants: A Systematic Review.JAMA network open · 2024Pooled it
- Adverse events associated with peanut oral immunotherapy in children - a systematic review and meta-analysis.Scientific reports · 2020Pooled it
- Dosing Reactions and Missed Doses Affect Peanut Oral Immunotherapy Outcomes.The journal of allergy and clinical immunology. In practice · 2026Trial
- Safety of a novel oral immunotherapy approach in preschool children with single and multiple food allergies.Frontiers in allergy · 2026Trial
- Peanut allergy oral immunotherapy drives single-cell multi-omic changes in peanut-reactive T cells associated with sustained unresponsiveness.Nature immunology · 2025Trial
- Baseline epitope-specific IgE profiles are predictive of sustained unresponsiveness or high threshold 1-year post oral immunotherapy in the POISED trial.The Journal of allergy and clinical immunology · 2025Trial
- Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: A randomized, placebo-controlled trial.The Journal of allergy and clinical immunology · 2024Trial
- CD8Nature communications · 2022Trial
- Kinetics of basophil hyporesponsiveness during short-course peanut oral immunotherapy.The Journal of allergy and clinical immunology · 2022Trial
- Oral desensitization therapy for peanut allergy induces dynamic changes in peanut-specific immune responses.Allergy · 2022Trial
- Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study.Lancet (London, England) · 2022Trial
- Gastrointestinal Eosinophil Responses in a Longitudinal, Randomized Trial of Peanut Oral Immunotherapy.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2021Trial
- Transcriptional changes in peanut-specific CD4+ T cells over the course of oral immunotherapy.Clinical immunology (Orlando, Fla.) · 2020Trial
- Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE.The Journal of allergy and clinical immunology · 2020Trial
- Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization.The Journal of allergy and clinical immunology · 2019Trial
- High- and low-dose oral immunotherapy similarly suppress pro-allergic cytokines and basophil activation in young children.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2019Trial
- Characterization of the B-cell receptor repertoires in peanut allergic subjects undergoing oral immunotherapy.Journal of human genetics · 2018Trial
- Baseline Gastrointestinal Eosinophilia Is Common in Oral Immunotherapy Subjects With IgE-Mediated Peanut Allergy.Frontiers in immunology · 2018Trial
- Taste aversion and adverse events contribute equally to OIT discontinuation in children: A real-world multi-allergen analysis.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Observational
85 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
16 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundOral immunotherapy (OIT) is an effective experimental food allergy treatment that is limited by treatment withdrawal and the frequent reversibility of desensitization if interrupted. Newly diagnosed preschool children may have clinical and immunological characteristics more amenable to treatment.
objectiveWe sought to test the safety, effectiveness, and feasibility of early OIT (E-OIT) in the treatment of peanut allergy.
methodsWe enrolled 40 children aged 9 to 36 months with suspected or known peanut allergy. Qualifying subjects reacted to peanut during an entry food challenge and were block-randomized 1:1 to receive E-OIT at goal maintenance doses of 300 or 3000 mg/d in a double-blinded fashion. The primary end point, sustained unresponsiveness at 4 weeks after stopping early intervention oral immunotherapy (4-SU), was assessed by double-blinded, placebo-controlled food challenge either upon achieving 4 prespecified criteria, or after 3 maintenance years. Peanut-specific immune responses were serially analyzed. Outcomes were compared with 154 matched standard-care controls.
resultsOf 40 consented subjects, 3 (7.5%) did not qualify. Overall, 29 of 37 (78%) in the intent-to-treat analysis achieved 4-SU (300-mg arm, 17 of 20 [85%]; 3000 mg, 12 of 17 [71%], P = .43) over a median of 29 months. Per-protocol, the overall proportion achieving 4-SU was 29 of 32 (91%). Peanut-specific IgE levels significantly declined in E-OIT-treated children, who were 19 times more likely to successfully consume dietary peanut than matched standard-care controls, in whom peanut-specific IgE levels significantly increased (relative risk, 19.42; 95% CI, 8.7-43.7; P < .001). Allergic side effects during E-OIT were common but all were mild to moderate.
conclusionsAt both doses tested, E-OIT had an acceptable safety profile and was highly successful in rapidly suppressing allergic immune responses and achieving safe dietary reintroduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.